Drugs / Bacillus subtilis DSM32444
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT05999955 | Dec 2022 → Apr 2023 | rhinitis, sinusitis | Huro Biotech Joint Stock Company | Completed | No outcome recorded |
| — | NCT05984004 | Sep → Nov 2022 | sinusitis | Huro Biotech Joint Stock Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bacillus subtilis DSM32444 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05999955 ↗ |
| Modality | Other / unclassified | “The aim of this study is to evaluate the safety of a nasal spray using a postbiotic preparation of Bacillus subtilis DSM32444 and that is a sterile inert bioparticle” NCT05999955 ↗ |
| Route | Intranasal | “The research product (SPEROVID or placebo) is nasally administered as a spray” NCT05984004 ↗ |